Promius to present data from Migraine MAST study at AAN 2018

MAST seeks to shed light on the current state of migraine symptom characteristics and illustrate the state of migraine treatment, including medication use and overuse, patterns of treatment delays, and barriers to access.

Promius Pharma LLC announces its presentations for the 70th American Academy of Neurology (AAN) Annual Meeting in Los Angeles, CA, April 21-27, 2018.

Promius will present 3 platform presentations, with one presentation selected for the “Best of” session, and 4 posters including data from the 2017 Migraine in America Symptoms and Treatment (MAST) Study, a longitudinal survey of more than 15,000 migraine patients.

Promius Pharma initiated MAST to address gaps in knowledge due to changing demographics and treatment options in the US migraine community. MAST seeks to shed light on the current state of migraine symptom characteristics, including the most bothersome migraine symptoms and how pain interferes with daily functioning. MAST will also illustrate the state of migraine treatment, including medication use and overuse, patterns of treatment delays, and barriers to access.

“The latest results from the MAST Study are new milestones in characterizing migraine symptoms,” said Richard B. Lipton, MD, Director of Montefiore Headache Center. “A better understanding of the migraine patient journey may help us optimize future treatment approaches.”

“Best of” session platform presentation:

• Untangling the Burden of Menstrual Migraine From Headache Frequency: Results from the 2017 MAST Study

Other platform presentations include:

• Predictors of Allodynia in Persons With Migraine: Results from the 2017 MAST Study
• Factors Associated With Medication Overuse In Persons With Migraine: Results from the 2017 MAST Study

The 4 posters are:

• MAST Study: Gender Differences In Treatment Patterns and Unmet Treatment Needs
• Most Bothersome Associated Symptom In Migraine: Results from 2017 MAST Study
• A Randomized, Double-Blind, Placebo-Controlled, Study Evaluating the Efficacy of DFN-02 (Nasal Spray of Sumatriptan 10 mg + Permeation Enhancer) in Migraine With or Without Aura
• Subjects With Episodic Migraine Treated With DFN-02 (Sumatriptan 10 mg + Permeation Enhancer) Report Higher Treatment Satisfaction and Reduced Functional Disability Compared With Placebo

“We are very excited to have such a robust representation of our scientific work at 70th AAN Annual Meeting” said Dr. Sagar Munjal, Vice President, Chief Medical Officer at Promius Pharma. “The MAST Study findings on the most bothersome symptoms is an excellent example of identifying key unmet needs in management of migraine. We are hopeful that DFN-02 will help address these unmet needs.”

About Pharmascroll:

Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease indications prevalent across the globe. The research conducted by Pharmascroll analysts is targeted to provide analytical and logical answers to the key business questions of the pharmaceutical and medical insights teams and to make better informed business decisions with the detailed relevant information available.

To read more news about Migraine, visit https://pharmascroll.com/news-category/migraine/

News Source: https://www.prnewswire.com/news-releases/progress-in-migraine-research-promius-announces-presentations-for-the-70th-american-academy-of-neurology-annual-meeting-300632971.html

Image Source: http://www.readersdigest.ca/health/conditions/8-ways-relieve-migraine/view-all/